Payment overview · 2025
General Payments
$137.50
7 reported records · 3 companies
Healthcare provider profile · identity verified
Katie Stucker, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ASH FLAT, AR · NPI 1083065015
Verified facts
What the public records show
CMS Open Payments records show Katie Stucker, APRN received $137.50 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 77.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106.26 | 77.3% | 5 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.18 | 12.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.06 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.50 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $106.26 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $106.26 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 559 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 89 |
| Lisinopril | Lisinopril | 404 | 96 |
| Losartan Potassium | Losartan Potassium | 379 | 87 |
| Omeprazole | Omeprazole | 300 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 293 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 285 | 62 |
| Gabapentin | Gabapentin | 280 | 64 |
| Sertraline Hcl | Sertraline Hcl | 246 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 58 |
| Furosemide | Furosemide | 216 | 50 |
| Tramadol Hcl | Tramadol Hcl | 208 | 50 |
| Meloxicam | Meloxicam | 206 | 48 |
| Potassium Chloride | Potassium Chloride | 190 | 42 |
| Metformin Hcl | Metformin Hcl | 183 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 60 |
| Trazodone Hcl | Trazodone Hcl | 180 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 36 |
| Glipizide Er | Glipizide | 157 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 39 |
| Famotidine | Famotidine | 140 | 32 |
| Clonazepam | Clonazepam | 134 | 29 |
| Eliquis | Apixaban | 132 | 28 |
| Montelukast Sodium | Montelukast Sodium | 130 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 36 |
| Simvastatin | Simvastatin | 127 | 32 |
| Glipizide | Glipizide | 126 | 31 |
| Alendronate Sodium | Alendronate Sodium | 122 | 27 |
| Ozempic | Semaglutide | 121 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 17 |
| Carvedilol | Carvedilol | 95 | 24 |
| Fenofibrate | Fenofibrate | 92 | 19 |
| Azithromycin | Azithromycin | 91 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 45 |
| Prednisone | Prednisone | 87 | 55 |
| Testosterone Cypionate | Testosterone Cypionate | 84 | 16 |
| Lorazepam | Lorazepam | 83 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 68 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 16 |
| Pregabalin | Pregabalin | 75 | 15 |
| Allopurinol | Allopurinol | 72 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 14 |
| Baclofen | Baclofen | 67 | 17 |
| Nystatin | Nystatin | 66 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 47 |
| Atenolol | Atenolol | 61 | 15 |
| Ezetimibe | Ezetimibe | 61 | 13 |
| Buspirone Hcl | Buspirone Hcl | 59 | 16 |
| Cephalexin | Cephalexin | 58 | 45 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 15 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 56 | 12 |
| Bupropion Xl | Bupropion Hcl | 52 | 12 |
| Ondansetron Odt | Ondansetron | 49 | 32 |
| Farxiga | Dapagliflozin Propanediol | 48 | 12 |
| Linzess | Linaclotide | 48 | suppressed |
| Celecoxib | Celecoxib | 47 | 11 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Fluconazole | Fluconazole | 44 | 26 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 18 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Cefdinir | Cefdinir | 37 | 33 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Sucralfate | Sucralfate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 28 |
| Arnuity Ellipta | Fluticasone Furoate | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Metolazone | Metolazone | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 11 |
| Torsemide | Torsemide | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 11 |
| Modafinil | Modafinil | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Kerendia | Finerenone | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Levemir | Insulin Detemir | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 16 |
| Nitroglycerin | Nitroglycerin | 21 | 15 |
| Alprazolam | Alprazolam | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Topiramate | Topiramate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.50 · 7 records | ABBVIE INC. | JOURNAVX, OTEZLA, QULIPTA, REPATHA, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error